.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AA07_Acenocoumarol.Acenocoumarol

Information

Acenocoumarol is a vitamin K antagonist oral anticoagulant, structurally related to warfarin, used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and for stroke prevention in atrial fibrillation. It is approved and used in several countries, though not in the United States.

Pharmacokinetics

Reported pharmacokinetic parameters in healthy adult volunteers after oral administration.

References

1. Thijssen, HH, et al., & de Vries-Hanje, JC (2001). Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clinical pharmacology and therapeutics 70(3) 292–298. DOI:10.1067/mcp.2001.117936 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11557918

2. Stehle, S, et al., & Fuhr, U (2008). Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clinical pharmacokinetics 47(9) 565–594. DOI:10.2165/00003088-200847090-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18698879

3. Villapalos-García, G, et al., & Abad-Santos, F (2023). NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 165 115058–None. DOI:10.1016/j.biopha.2023.115058 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37385211

Revisions

• 06/2025 initial generated model